Major Depressive Disorder

Neurolief’s physician-directed therapy brings supervised, noninvasive brain stimulation into the home for adults with MDD who have not responded to ≥ 1 antidepressant.

A retrospective cohort analysis reports data on a two-sided relationship between depression diagnosis and chronic kidney disease progression.

Meta-analysis shows exercise may match therapy in improving depressive symptoms, with moderate-intensity and 13–36 sessions offering the greatest benefit.

A study found that low-intensity transcranial ultrasound stimulation targeting the left dlPFC improves depression while avoiding common side effects associated with TMS and tDCS.

Q4 2025 psychiatry highlights: FDA approvals, clearances, and submissions, plus new clinical data shaping personalized treatment in MDD, bipolar, and schizophrenia.

A study found no differences in depressive symptom reduction when nonresponders continued therapy, switched therapists, or changed both therapist and treatment approach.

A study identified early symptom improvement and greater baseline depression severity as predictors of sustained antidepressant response to adjunctive cariprazine in MDD.

December 2025 psychiatry updates: Teva files TEV-‘749 for schizophrenia, lumateperone boosts MDD outcomes, AGA tied to mental health, and a look back at 2025 advances.

In 2025, psychiatry saw major FDA approvals, novel treatments, and pivotal clinical updates that are transforming care for depression, ADHD, schizophrenia, and anxiety.

New phase 3 data support the FDA approval of lumateperone, showing early efficacy and favorable tolerability as an adjunctive treatment for MDD.

Following its 2025 FDA approval, lumateperone 42 mg demonstrated meaningful reductions in MADRS and CGI-S scores in adults with major depressive disorder.

As the FDA strengthens AI standards after its recent meeting, a new AI-assisted genetic tool shows promise for pinpointing patients who may respond to a vasopressin blocker.

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

This month in review highlights November’s biggest psychiatry stories, including FDA moves, phase 4 findings, and new data on digital mental health tools.

A study showed that users readily adopt mental health apps, but adherence and follow-up completion lag; reminders and human support improve engagement.

Phase 4 double-blind data reveal improved remission, but no significant difference in response between perospirone and placebo.

FDA clears BrainsWay's Deep TMS for adolescents aged 15-21 years with major depressive disorder (MDD), expanding its use.

This month in review spotlights the top psychiatry news from October 2025, featuring FDA's approval of UZEDY for bipolar I disorder.

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Study finds repetitive transcranial magnetic stimulation brings clinically meaningful improvements in quality of life for adults with MDD through 12 weeks.

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.